• 대한한의학방제학회지
• /
• 제20권1호
• /
• pp.67-80
• /
• 2012

Objectives : We investigated the effects of Ingecheonggeumdan(ICD) on body weight and examined whether blood lipid levels and visceral fat are inhibited by it in high fat diet-fed obese male mice. Methods : 8 weeks old, high fat diet-fed obese male mice were divided into 6 groups: C57BL/6N normal, control, ICD-1(150mg/kg), ICD-2(300mg/kg), ICD-3(600mg/kg) and orlistat(10mg/kg). After mice were treated with ICD and orlistat for 8 weeks, we measured body weight gain, food intake, feeding efficiency ratio, fat weight, plasma leptin and lipid levels. We also performed histological analysis for liver and fat on the mice. Results : Compared with controls, ICD and orlistat-treated mice had lower body weight gain and adipose tissue weight, the magnitudes of which were prominent in ICD-3. Compared with controls, ICD and orlistat-treated mice had lower blood leptin levels, the magnitude of which was prominent in ICD-3. Compared with controls, ICD and orlistat-treated mice had higher blood HDL-cholesterol and lower blood plasma LDL-cholesterol, free fatty acid and triglyceride levels, the magnitudes of which were prominent in ICD-3. Blood plasma AST and ALT concentrations were not changed by ICD and orlistat, indicating ICD and orlistat do not show any toxic effects. Consistent with their effects on body weight gain, the size of adipocytes and hepatic lipid accumulation were significantly decreased by ICD and orlistat. Conclusions : These results demonstrate that ICD and orlistat effectively reduce body weight gain, blood plasma LDL-cholesterol, free fatty acid and triglyceride levels and improves abdominal fat, the magnitudes of which were prominent in ICD-3.

• 한국식품영양과학회지
• /
• 제38권11호
• /
• pp.1522-1527
• /
• 2009

우리는 고지방식이에 의해 유도된 비만 마우스의 몸무게, 부고환 지방조직 무게, 부고환 지방조직의 지방세포 크기 및 혈장 지질 농도에 약용식물 물 추출물들(MPWEs) 혼합식이가 어떤 영향들을 미치는지 연구하였다. MPWEs 혼합식이의 항비만 효과를 알아보기 위하여 C57BL/6J 마우스는 11주 동안 고지방식이를 섭취시켰다. 마지막 6주 동안, 계속해서 고지방식이(HFD)만 섭취시키거나 고지방식이에 MPWEs(5 g/kg, HFD＋MPWEs)이나 고지방식이에 orlistat[0.5 g/kg, HFD＋orlistat(항비만 약)]을 섞어 섭취시켰다. HF-free군은 11주 동안 일반 식이를 섭취시켰다. 11주간 고지방식이를 섭취한 군은 일반식이군과 비교하여 혈장 지질 수준, 몸무게, 간 무게 및 부고환 지방조직 무게가 현저하게 증가하였다. MPWEs를 함유하고 있는 식이는 몸무게, 간 무게 및 부고환 지방조직 무게와 마찬가지로 혈장 총콜레스테롤, LDL 콜레스테롤, 중성지방 그리고 혈당 농도를 현저하게 감소시켰다. 혈장 중성지방 수준은 6주 동안 orlistat를 함유한 고지방식이군(HFD＋orlistat)에서 현저히 낮았고 MPWEs를 함유한 고지방식이군(HFD＋MPWEs)의 그것과 유사하였다. 고지방식이군 마우스의 지방세포크기가 일반식이군의 그것에 비해 현저하게 증가하였고, MPWEs와 orlistat(positive control)는 부고환 지방세포 크기를 현저하게 감소시켰으나 orlistat가 MPWEs보다 약간 더 영향력이 있었다. 이들 결과들은 MPWEs 섭취는 몸무게 증가, 지방세포 형성 및 지방세포 크기 증가를 저해함으로써 항비만 효과가 있을 것이라는 것을 시사하고 있다.

• Toxicological Research
• /
• 제22권4호
• /
• pp.339-348
• /
• 2006

Misaengtang (MST), a formula of Korean herbal medicines, has been used as a weight-controlling recipe. We have investigated two experiment of body weight regulation by MST In rats. i) The anti-obesity effect of MTS on a high fat diet-induced obesity, male Sprague-Dawley rats were fed with a high-fat diet containing 30% in the absence or presence of MST (0.3, 1 or 3%) or a reference orlistat (0.05%) for 6 weeks. ii) weight-decrease effect of MST on normal diet, same animal were fed with a normal diet in the absence or presence of MST (3%) for 6 weeks. And the body weights, daily feed and water consumptions, organ weights, fat weights serum biochemistry were measured. In both experiments, MST and orlistat did not affect the body weight gain. But orlistat significantly increased the feed and water consumptions, leading to low-feed efficiency, and orlistat markedly reduced abdominal, paratesticular and perirenal fat weights, although increased the kidney weights. In MST, low dose (0.3%) of MST decreased the perirenal fat and increased the kidney weights in rats fed HFD, and MST 3% decreased the abdominal fat weights in rats fed normal diet. In addition, Orlistat caused changes in parameters of hepatotoxicity (AST and glucose), nephrotoxicity (BUN and B/C ratio) and lipid metabolism (HDL and triglycerides). In comparison, MST decreased AST, ALP and ALT, the hepatotoxicity markers, and somewhat improved the hepatic fatty degeneration. Taken together, it is suggested that MST does not exert anti-obesity activity as well as remarkably direct effects, but MST may be potentially benefit for dietary cure and exercise-cure of obesity.

• Korean Chemical Engineering Research
• /
• 제54권2호
• /
• pp.223-228
• /
• 2016

본 논문은 PDMS을 기반으로 한 미세접촉인쇄법을 사용하여 보다 효율적으로 지방세포를 선택적으로 배양접시에 부착시켰으며 패터닝 된 배양접시에서 지방세포가 빠르게 지방분화를 가능하게 하였다. PDMS을 이용한 선택적 표면 처리 방법은 기존의 세포칩 제작과 달리 소량의 유기용매사용, 저가의 장비 사용, 또한 효율적으로 특정 지역 안에서 지방세포를 고정화하고 성장시킬 수 있으며 이를 통해 지방세포의 생리학적 상태를 손쉽게 관찰할 수 있는 분석 기술로 활용된다. 이렇게 구성된 지방세포칩 위에 대표적인 비만 억제제 약물인 Orlistat을 $0.2{\mu}M{\sim}5.0{\mu}M$ 농도로 처리하였을 때 대조군에 비하여 최대 26.5%의 억제 효과가 나타남을 확인하였다. 따라서, 본 논문에서 제안하는 방법을 통하여 다양한 비만 억제제 약물 탐색을 위한 세포칩으로 활용이 가능할 것으로 기대된다.

• The Korean Journal of Physiology and Pharmacology
• /
• 제15권1호
• /
• pp.43-51
• /
• 2011

Natural products in Chonnam, Korea were screened via anti-angiogenesis experiments, and 1 candidate product was identified, Corni fructus, which exerted dose-dependent inhibitory effects against angiogenesis, adipogenesis, and cell adhesion. C. fructus extract (CFE) exhibits an angiogenesis inhibitory effect superior to that of the EGCG from green tea leaves. The expression level of angiogenesis and adipogenesis-related signal molecules in the western blotting was reduced by increasing the amount of added CFE. Moreover, a diet supplemented with CFE was deemed more effective in inducing weight loss in LB mice than a representative synthetic diet drug, orlistat, which incidently caused the side effect of denuding the mice of their hair. These results indicate that C. fructus may prove to be a useful anti-adipogenic compound, and these in vitro results may be reflected later under in vivo conditions.

• 생명과학회지
• /
• 제16권2호
• /
• pp.328-332
• /
• 2006

Pancreatic lipase의 활성을 저해하는 물질을 탐색하고자 국내의 식용 또는 약용식물의 추출물을 대상으로 lipase 활성에 대한 저해능력이 있는 식물추출물은 탐색한 결과 대복피, 계혈등, 오배자 및 백자인의 식물추출물을 선정하였다. Pancreatic lipase에 대한 저해활성이 우수한 백자인으로부터 클로로포름 용매추출, 실리카겔 컬럼크로마토그라피, 세파덱스 LH-20 컬럼크로마토그라피와 고속액체크로마토그라피를 실시하여 pancreatic lipase에 대한 저해활성 물질로 TF-1, TF-2, TF-3를 분리하였다. 이들을 대상으로 porcine pancreatic lipase에 대한 저해효과를 측정한 결과, 활성물질 TF-1, TF-2, TF-3 및 orlistat의 porcine pancreatic lipase에 대한 $IC_{50}$ 값은 각각 44.7, 98.7, 46.1 및 $27.6{\mu}g/ml$인 것으로 나타났다. 활성물질 TF-2와 orlistat의 경우에는 $10{\mu}g/ml$의 농도에서 NIH-3T3 L1의 지방세포로의 분화에도 억제효과가 있음을 입증하였다.

• Nutrition Research and Practice
• /
• 제2권4호
• /
• pp.200-203
• /
• 2008

Obesity has become a worldwide health problem. Orlistat, an inhibitor of pancreatic lipase, is currently approved as an anti-obesity drug. However, gastrointestinal side effects caused by Orlistat may limit its use. In this study the inhibitory activities of dandelion (Taraxacum officinale) against pancreatic lipase in vitro and in vivo were measured to determine its possible use as a natural anti-obesity agent. The inhibitory activities of the 95% ethanol extract of T. officinale and Orlistat were measured using 4-methylumbelliferyl oleate (4-MU oleate) as a substrate at concentrations of 250, 125, 100, 25, 12.5 and $4\;{\mu}g/ml$. To determine pancreatic lipase inhibitory activity in vivo, mice (n=16) were orally administered with com oil emulsion (5 ml/kg) alone or with the 95% ethanol extract of T. officinale (400 mg/kg) following an overnight fast. Plasma triglyceride levels were measured at 0, 90, 180, and 240 min after treatment and incremental areas under the response curves (AUC) were calculated. The 95% ethanol extract of T. officinale and Orlistat, inhibited, porcine pancreatic lipase activity by 86.3% and 95.7% at a concentration of $250\;{\mu}g/ml$, respectively. T. officinale extract showed dose-dependent inhibition with the $IC_{50}$ of $78.2\;{\mu}g/ml$. A single oral dose of the extract significantly inhibited increases in plasma triglyceride levels at 90 and 180 min and reduced AVC of plasma triglyceride response curve (p<0.05). The results indicate that T. officinale exhibits inhibitory activities against pancreatic lipase in vitro and in vivo. Further studies to elucidate anti-obesity effects of chronic consumption of T. officinale and to identify the active components responsible for inhibitory activity against pancreatic lipase are necessary.

• 정신신체의학
• /
• 제22권2호
• /
• pp.63-70
• /
• 2014

기분장애에서 과체중과 비만의 문제가 일반인구보다 더 심각하고, 심혈관 치명률의 증가와 무관하지 않기 때문에 비만에 대한 치료가 필수적이다. 일반적인 상황에서 비만에 대한 치료와 동일하게 생활습관교정과 같은 비약물치료가 선행되어야 한다. 이 같은 시도가 실패하는 경우에는 약물치료가 필요하다. 기분장애의 비만치료로 공식 승인된 약은 없다. 따라서 일반인구의 비만에 승인된 약을 처방하거나 여러 연구를 통해서 효과가 입증된 약을 처방하게 된다. 여러 치료 지침과 연구 등은 orlistat, metformin, topiramate와 bupropion 등이 효과적임을 지지한다.

• Biomolecules & Therapeutics
• /
• 제17권4호
• /
• pp.348-352
• /
• 2009

Over the last decade, the incidence of overweight and obesity has nearly doubled in many countries and is considered a pandemic. Obesity was identified as a major risk factor for cardiovascular disease as the same level as smoking and diabetes. Visceral fat is considered one of the key contributors to outcome and certain ethnic groups such as Asians seem to be more affected than others. Weight reduction through lifestyle changes was found to be impactful to improve overall health, but weight loss and maintenance thereof is limited and difficult to sustain. Surgical intervention demonstrated a greater weight loss in the severely obese and was associated with improved all-cause mortality. Despite numerous pharmacological targets and a high medical need, only few drugs have been successfully developed. Earlier studies with amphetamine-derived compounds showed significant weight loss but their critical safety profiles led to market withdrawals and disappointment. More recent compounds; orlistat - a lipase inhibitor, rimonabant - a cannaboid-1-receptor antagonist, and sibutramine - a combined serotonin/norepinephrine re-uptake inhibitor, all demonstrated similar significant efficacy; however, they carry specific safety profiles making them unsuitable for every patient. The main limitation of pharmacotherapy is the absence of clear benefit-risk assessments through outcome studies. Such a study - the SCOUT trial - was designed to compare sibutramine versus placebo and the effect on morbidity and mortality in nearly 10,000 obese patients with additional risk factors. Such studies could provide new scientific evidence for obesity treatment and may support future pharmacological approaches.

• 한방재활의학과학회지
• /
• 제26권2호
• /
• pp.1-12
• /
• 2016

Objectives The purpose of this study was to evaluate anti-obesity effect of Galgeuntang (gegentang) and elucidate the effect of it on gene expression related to obesity. Methods The experiments were performed with the use of Diet-Induced Obese mice. They were grouped NC (normal control), HFD (high fat diet control), GGT (Galgeun-tang (gegentang), 700 mg/kg), ORL (Orlistat, 10 mg/kg). GGT was orally administered for 12 weeks. Body weight was measured every week. Real-time PCR was performed to investigate the effect of GGT on gene expression in liver tissue. Results GGT group and ORL group were reduced in body weight compared with HFD. HFD increased $PPAR{\gamma}$, SREBP-1, Leptin, aP2, FATP1, FAS gene expression compared with NC. GGT increased FATP1 gene expression. But GGT reduced $PPAR{\gamma}$ & FAS gene expression in liver tissue of diet-induced obese mice compared with HFD. Conclusions These results suggest that GGT is supposed to have a certain impact on the treatment of obesity. But more study is needed in the future.